Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system

Lipids Health Dis. 2018 Jul 28;17(1):178. doi: 10.1186/s12944-018-0824-3.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) can develop in prenatal stages and can be exacerbated by exposure to a postnatal high-fat (HF) diet. We investigated the protective effects of resveratrol on prenatal and postnatal HF diet-induced NAFLD.

Methods: Male Sprague-Dawley rat offspring were placed in five experimental groups (n = 10-12 per group): normal diet (VNF), maternal HF diet (ONF), postnatal HF diet (VHF), and maternal HF diet/postnatal HF diet (OHF). A therapeutic group with resveratrol for maternal HF diet/postnatal HF diet (OHFR) was used for comparison. Resveratrol (50 mg/kg/day) was dissolved in drinking water for offspring from post-weaning to postnatal day (PND) 120.

Results: We found that HF/HF-induced NAFLD was prevented in adult offspring by the administration of resveratrol. Resveratrol administration mediated a protective effect on rats on HF/HF by regulating lipid metabolism, reducing oxidative stress and apoptosis, restoring nutrient-sensing pathways by increasing Sirt1 and leptin expression, and mediating the renin-angiotensin system (RAS) to decrease angiotensinogen, renin, ACE1, and AT1R levels and increased ACE2, AT2R and MAS1 levels compared to those in the OHF group.

Conclusion: Our results suggest that a maternal and post-weaning HF diet increases liver steatosis and apoptosis via the RAS. Resveratrol might serve as a therapeutic target by mediating protective actions against NAFLD in offspring exposed to a combination of maternal and postnatal HF diet.

Keywords: High-fat diet; Nonalcoholic fatty liver disease (NAFLD); Renin-angiotensin system (RAS); Resveratrol.

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Angiotensinogen / genetics
  • Angiotensinogen / metabolism
  • Animals
  • Animals, Newborn
  • Diet, High-Fat / adverse effects
  • Female
  • Gene Expression Regulation / drug effects*
  • Hypolipidemic Agents / pharmacology*
  • Leptin / genetics
  • Leptin / metabolism
  • Lipid Metabolism / drug effects
  • Male
  • Maternal Nutritional Physiological Phenomena
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / genetics
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Oxidative Stress / drug effects
  • Peptidyl-Dipeptidase A / genetics
  • Peptidyl-Dipeptidase A / metabolism
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Angiotensin, Type 1 / genetics
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptor, Angiotensin, Type 2 / genetics
  • Receptor, Angiotensin, Type 2 / metabolism
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, G-Protein-Coupled / metabolism
  • Renin / genetics
  • Renin / metabolism
  • Renin-Angiotensin System / drug effects*
  • Resveratrol
  • Sirtuin 1 / genetics
  • Sirtuin 1 / metabolism
  • Stilbenes / pharmacology*
  • Weaning

Substances

  • Hypolipidemic Agents
  • Leptin
  • Mas1 protein, rat
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins
  • Receptor, Angiotensin, Type 1
  • Receptor, Angiotensin, Type 2
  • Receptors, G-Protein-Coupled
  • Stilbenes
  • Angiotensinogen
  • Peptidyl-Dipeptidase A
  • Ace2 protein, rat
  • Angiotensin-Converting Enzyme 2
  • Renin
  • Sirt1 protein, rat
  • Sirtuin 1
  • Resveratrol